We enable the acceleration of life science research
and development in the pursuit of improved human health

About AiPharma

AiPHARMA is an early-stage biotechnology company with regional offices in Boston, Dubai, Tokyo, Singapore and Hong Kong. We take a highly interdisciplinary approach to science, with our services building upon work from leading academic labs in biophysics and algorithmic design that enables the acceleration of life science research and development in the pursuit of improved human health.

Global Response Aid (GRA)

At the stage where COVID-19 was declared a pandemic, we quickly deployed a crew to start an initiative, that later became a full-fledged company called Global Response Aid. Alongside Agility which is one of the world’s leading logistics companies with a presence in 100 countries and annual turnover of $5BN.
 

PREPAiRE

PREPAiRE aims to provide reliable early warning on potential pandemics, but more importantly, to provide governments, health care professionals and business with the tools to predict, and understand the characteristics of the threat and the forecast consequences on the demand of PPE, medical devices and drugs.

 
 

PARTNERS

weblogo3-01.png
muna.jpg
NAS_logo.5a33ccaa14043 (1).png
 

OUR TEAM

omar-q.jpg

Omar Quandeel

Chairman of the Board

jeff.jpg

Jeff Snide
Chief Financial Officer

david.jpg

David Howe
Chief Operating Officer

Ivaylo-Vladimirov-Tsanev.jpg

Ivaylo Vladimirov Tsanev

Chief Regulatory Officer

moorie.jpg

Alasdair Moore
Director

mary.jpg

Mary O’Brian
Chief Marketing Officer

brett.jpg

Brett Wight
Chief Commercial Officer

omar.jpg

Omar Arrab

Director

jew.jpg

John White
Group Legal Counsel

abdulla.jpg

Abdulla Al Mansoori

Director of AiPharma MENA

elvira.jpg

Elvira Pleshakova
SVP Legal

 

NEWS

 

September 23, 2020

Fujifilm to seek approval for Avigan in Covid-19 after positive data

Japan's Fujifilm Toyama Chemical plans to seek approval for its anti-viral drug Avigan (favipiravir) to treat patients with Covid-19, after obtaining positive results in a Phase III clinical trial.

September 23, 2020

Fujifilm's flu drug Avigan improves COVID-19 recovery time, setting up filing in Japan

Six months after the World Health Organization declared COVID-19 a global pandemic, the list of drugs with proven efficacy against the virus remains short. On Wednesday, Fujifilm added its flu drug Avigan.

September 23, 2020

Anti-influenza drug Avigan® TabletMeets Primary Endpoint in Phase III Clinical Trial in Japan for COVID-19 patients

TOKYO, September 23, 2020—FUJIFILM Toyama Chemical Co., Ltd. (President: Junji Okada; hereinafter “FUJIFILM Toyama Chemical”) has announced today that primary endpoint has been met in phase III clinical trial of “Avigan Tablet” 

September 23, 2020

Avigan® Shows Promising Results in Treatment of COVID Patients in Japan

Healthcare solutions provider Global Response Aid (GRA) and Dr. Reddy's Laboratories (NYSE: RDY) announced that the anti-viral drug Avigan® produced promising results in a single-blinded, placebo-controlled Phase 3 clinical study conducted in Japan with the sponsorship of FujiFilm Toyama Chemical.

September 20, 2020

International Cooperation in Clinical Studies: Richard H. Kaszynski / MD, Ph.D., Co-Founder and Director of Stanford Solutions

Richard H. Kaszynski formed a global network to rapidly conduct clinical drug trials in order to fight against infectious disease pandemics. He talks about a promising drug candidate for COVID-19.

September 28, 2020

Clinical Catch-Up: September 21-25

The European Society of Medical Oncology (ESMO) Virtual Congress 2020 was last weekend and the beginning of the week, which resulted in numerous clinical trial announcements. Here’s a look.

CONTACT US

 

AiPharma 
ONE JLT Tower 14th floor
Jumeriah Lake Towers ,Dubai, 103805
United Arab Emirates

Our Projects

© 2020 by AiPharma

Disclaimer

This Website contains statements, names and references, but not limited to past or forward-looking events or features.
Potential risks and uncertainties include factors as general usage, implementation or applications restricted by laws and regulations are part of the disclaimers.